Anhydrous Formulation for Hydrolysis-Prone (S)-Piperidine-2,6-dione
Solution Overview
Problem
Compound A, (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, is prone to hydrolysis, posing chemical stability challenges and requiring pharmaceutical excipients tailored to achieve advantageous physical and pharmaceutical properties for effective dosage forms in treating immune-related and inflammatory diseases.
Innovation Solution
Development of pharmaceutical dosage forms of Compound A, including pharmaceutically acceptable prodrugs, salts, solvates, hydrates, clathrates, stereoisomers, tautomers, or racemic mixtures, formulated with anhydrous excipients to enhance stability and bioavailability, and methods for their administration in treating various immune-related and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If Compound A is formulated with conventional excipients, then ease of manufacture is improved, but chemical stability deteriorates due to hydrolysis
Solution Approach 1:
The patent changes the physical and chemical parameters of the excipients by specifying anhydrous conditions and controlled moisture content (less than 10%, preferably less than 5%). This parameter change prevents hydrolysis of Compound A while maintaining ease of manufacture through standardized anhydrous excipient selection
Solution Approach 2:
The patent introduces anhydrous excipients as intermediaries that mediate between Compound A and moisture. These excipients create a protective environment that prevents direct contact between Compound A and water, thereby preventing hydrolysis while maintaining manufacturability
2Stability of the object's composition
If refrigeration is used to maintain stability, then chemical stability is improved, but ease of operation deteriorates due to storage requirements
Solution Approach 1:
The formulation achieves self-service stability through intrinsic design features: anhydrous excipients and moisture control mechanisms are built into the formulation itself, enabling the product to maintain stability without external refrigeration services. The dosage form autonomously protects Compound A from hydrolysis
Solution Approach 2:
The patent creates an inert, anhydrous environment within the dosage form by selecting excipients with less than 10% moisture content. This inert environment excludes water from the system, preventing hydrolysis without requiring refrigeration, thereby improving ease of operation
3Ease of operation
If standard dosage forms are used, then ease of administration is improved, but bioavailability deteriorates due to hydrolysis
Solution Approach 1:
The patent applies preliminary action by pre-protecting Compound A against hydrolysis through anhydrous formulation design before administration. The stability保护措施 are built into the dosage form itself, ensuring that when the patient administers the medication, the compound is already protected and ready for effective absorption
Solution Approach 2:
The patent changes the moisture content parameter of the dosage form to less than 10% (preferably less than 5%), which prevents hydrolysis and maintains Compound A's integrity through administration. This parameter change ensures both ease of administration and high bioavailability
Data Source
AI summary
Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.